

TAKE ADVANTAGE OF

2025 Medicare changes to help manage costs for NUBEQA® (darolutamide)

Opt in to the Medicare Prescription Payment Plan today



NOW IN EFFECT FOR 2025

Under Medicare Part D, your 2025 out-of-pocket costs are capped at \$2,000.

You can also **elect to participate in the Medicare Prescription Payment Plan**—an optional program to **help manage your out-of-pocket drug costs by spreading them out** over the year.

HOW IT WORKS

1 Opt in to participate

Opt in now to ensure your benefits start as soon as possible




ONLINE

- or -



MAIL

Complete and submit an election request form,
available on your plan's website



PHONE

Call your plan
and request to participate

2 Pay nothing up front

3 Pay monthly installments to your plan

You will only be billed for what you spend toward the
\$2,000 out-of-pocket cap


NUBEQA®
(darolutamide) 300 mg tablets

Frequently Asked Questions

› Am I eligible to participate in the Medicare Prescription Payment Plan?

Anyone with a Medicare Part D prescription drug plan (including Medicare Advantage plans with drug coverage) is eligible to opt in to the Medicare Prescription Payment Plan. This program is optional and you must opt in to participate.

› How do I know if the Medicare Prescription Payment Plan is right for me?

While this program is available to anyone with Medicare Part D, it may be particularly helpful if you use medications with high out-of-pocket costs (such as branded or specialty drugs) and are likely to reach the \$2,000 out-of-pocket spending cap earlier in the year. Visit [medicare.gov/prescription-payment-plan/will-this-help-me](https://www.medicare.gov/prescription-payment-plan/will-this-help-me) to see if this payment option is right for you.

› What will change for me if I opt in to the Medicare Prescription Payment plan?

Instead of paying the pharmacy for your prescriptions, you will pay your plan over the year in capped monthly installments. Your maximum monthly payments will be calculated based on what you have spent toward the \$2,000 out-of-pocket limit and the number of remaining months in the plan year.

› Is there a deadline to opt in for 2025?

You can opt in any time in 2025. Opting in early is recommended. Until you are enrolled, you will continue to pay your full copay amount when the prescription is filled instead of smoothing out the payments over the remaining months of 2025.

› What if I do not reach the \$2,000 out-of-pocket cap?

You will only be billed for what you spend toward the out-of-pocket cap and do not have to reach or pay the full \$2,000 limit as a condition of participating in the program.

› Are there any costs or fees to participate?

There is no cost to participate in the Medicare Prescription Payment Plan.

› What medications are included in this program?

All drugs covered by your Part D plan, including NUBEQA® (darolutamide), other brands, and generics, qualify toward your annual out-of-pocket costs and will be billed as part of your monthly installment benefit until you reach the \$2,000 spending cap.

› How does this program differ from the Low Income Subsidy “Extra Help” program?

The Extra Help program reduces qualifying members’ total out-of-pocket drug costs, whereas the Medicare Prescription Payment Plan helps “smooth” these costs into more manageable monthly payments instead of a lump sum early in the year. For more information about the Extra Help program, please call [1-800-772-1213](tel:1-800-772-1213) or visit www.ssa.gov/extrahelp.

Where can I find more information about the Medicare Prescription Payment Plan?

To learn more, please call your plan or visit your plan’s website. Additional information, including a preview of your estimated monthly and annual costs, can be found at [medicare.gov/prescription-payment-plan](https://www.medicare.gov/prescription-payment-plan) or by calling [1-800-MEDICARE \(1-800-633-4227\)](tel:1-800-MEDICARE). TTY users can call [1-877-486-2048](tel:1-877-486-2048).

OPT IN NOW to get the maximum benefit in 2025



© 2024 Bayer. BAYER, the Bayer Cross, and NUBEQA are registered trademarks of Bayer.
MAC-NUB-US-0475-1 11/24

